Strongbridge biopharma plc (SBBP)
Income statement / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15
Revenues:
Total revenues

6,674

5,606

5,684

6,079

4,343

4,514

5,347

4,296

3,870

-

2,533

1,529

-

-

-

-

-

-

-

-

-

Total revenues

-

-

-

-

-

-

-

-

-

-

2,533

1,529

-

-

-

-

-

-

-

-

-

Cost and expenses:
Cost of sales (excluding amortization of intangible asset)

969

986

1,001

1,022

813

-

1,441

753

-

-

-

-

-

-

-

-

-

-

-

-

-

Cost of sales (excluding amortization of intangible assets)

-

-

-

-

-

-

-

-

667

-

591

377

-

-

-

-

-

-

-

-

-

Selling, general and administrative

10,403

11,970

12,806

12,182

12,100

16,200

19,564

15,210

12,362

10,224

8,484

10,142

7,442

3,615

3,117

4,014

4,129

-

-

-

-

Research and development

7,552

8,029

7,552

8,739

6,583

7,909

7,198

5,453

4,881

5,155

4,504

4,128

3,481

4,141

4,516

4,572

6,794

5,807

4,110

7,718

2,500

Amortization of intangible asset

1,256

1,256

1,255

1,255

1,256

1,670

1,876

1,872

1,769

1,255

1,256

1,255

1,256

-

-

-

-

-

-

-

-

General and administrative

-

-

-

-

-

-

-

-

-

-

-

-

-

-

3,117

-

-

-

5,535

9,512

3,108

Impairment of intangible asset

-

-

-

-

-

-

-

-

-

-

20,723

-

-

-

-

-

-

-

-

-

-

Impairment of intangible asset

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

5,228

-

-

-

-

-

Total cost and expenses

20,180

22,241

22,614

23,198

20,752

26,904

30,079

23,288

19,679

17,149

35,558

15,902

12,179

-

-

13,814

-

-

-

-

-

Total operating expenses

-

-

-

-

-

-

-

-

-

-

-

-

-

-

7,633

-

10,923

-

9,645

17,230

5,608

Operating loss

-13,506

-16,635

-16,930

-17,119

-16,409

-22,390

-24,732

-18,992

-15,809

-14,165

-33,025

-14,373

-12,179

-18,356

-7,633

-13,814

-10,923

-10,371

-9,645

-17,230

-5,608

Other income (expenses), net:
Unrealized gain (loss) on fair value of warrants

-580

-1,307

-3,202

-8,697

1,820

111

-7,131

-19,017

9,700

2,024

-1,953

15,219

14,928

-

-

-

-

-

-

-

-

Income from field services agreement

-

7,150

1,725

1,725

2,016

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Expense from field services agreement

-

993

1,672

1,758

2,229

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Interest expense

-

-

-

-

-

2,965

3,387

3,289

2,874

1,475

1,364

737

737

-

-

-

-

-

-

-

-

Foreign exchange loss

-

-

-

-

-

-

-

-

-

-

-11

-14

-12

-5

-20

3

-47

326

-136

466

-780

Loss on extinguishment of debt

-

-

-

-

-

-21,049

0

0

-500

-

-3,545

-

-

-

-

-

-

-

-

-

-

Other income, net

228

191

576

608

685

273

430

342

160

-1

82

60

-35

31

35

44

-1,290

-549

-13

-502

-41

Total other income (expenses), net

808

7,655

3,831

9,272

-1,348

106,980

4,174

16,070

-12,914

-3,463

-2,885

-15,910

-15,712

644

15

47

-1,337

-223

-149

-36

-821

Loss before income taxes

-12,698

-8,980

-13,099

-7,847

-17,757

84,590

-20,558

-2,922

-28,723

-17,628

-35,910

-30,283

-27,891

-17,712

-7,618

-13,767

-12,260

-10,594

-9,794

-17,266

-6,429

Income tax expense

0

0

691

400

677

-

-

1

-

1,119

-850

-92

1,594

-1,712

0

-871

-55

-144

-128

-123

-55

Net income (loss)

-

-

-

-

-

-

-

-

-

-

-

-

-

-16,000

-7,618

-12,896

-12,205

-10,450

-9,666

-17,143

-6,374

Net income (loss) attributable to non-controlling interest

-

-

-

-

-

-

-

-

-

-

-

-

-

1

-17

-55

-51

-

-10

-

-

Net loss

-12,698

-8,980

-13,790

-8,247

-18,434

84,055

-20,558

-2,923

-28,723

-18,747

-35,060

-30,191

-29,485

-16,001

-7,601

-12,841

-12,154

-10,407

-9,656

-17,143

-6,374

Unrealized gain on marketable securities

3

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Comprehensive loss

-12,695

-

-

-

-18,434

-

-

-

-

-

-

-

-

-

-7,601

-

-

-

-9,656

-17,143

-6,374

Net loss attributable to ordinary shareholders:
Basic and diluted

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-7,601

-12,841

-12,154

-

-9,656

-17,143

-6,374

Basic

-12,698

-8,980

-13,790

-8,247

-18,434

84,055

-20,558

-2,923

-28,723

-

-35,060

-30,191

-

-

-

-

-

-

-

-

-

Diluted

-13,278

-8,467

-16,992

-16,944

-18,434

93,867

-27,690

-21,940

-28,723

-

-35,060

-30,191

-

-

-

-

-

-

-

-

-

Net loss per share attributable to ordinary shareholders:
Basic (in dollars per share)

-0.23

-0.17

-0.25

-0.15

-0.34

-

-0.44

-0.06

-

-

-0.98

-0.86

-

-

-

-

-

-

-

-

-

Diluted (in dollars per share)

-0.24

-0.15

-0.31

-0.30

-0.34

-

-0.55

-0.43

-

-

-0.98

-0.86

-

-

-

-

-

-

-

-

-

Basic and diluted (in dollars per share)

-

-

-

-

-

-

-

-

-0.66

-

-

-

-0.83

-

-0.36

-0.61

-0.57

-

-0.51

-1.19

-0.52

Weighted-average shares used in computing net loss per share attributable to ordinary shareholders:
Basic and diluted

-

-

-

-

-

-

-

-

43,620

-

-

-

35,335

-

21,205

21,205

21,205

-

18,784

14,461

12,292

Basic (in shares)

54,231

54,206

54,192

54,175

54,155

-

46,978

45,829

-

-

35,716

35,335

-

-

-

-

-

-

-

-

-

Diluted (in shares)

54,444

57,055

54,540

55,781

54,155

-

50,317

50,437

-

-

35,716

35,335

-

-

-

-

-

-

-

-

-

Product
Total revenues

6,663

5,593

5,677

6,073

4,333

4,514

5,347

4,296

3,870

-

-

-

-

-

-

-

-

-

-

-

-

Royalty
Total revenues

11

13

7

6

10

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-